department

Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access

therapeutic area

Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease

location & type

Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →

when

Latest
Archive

by source

All Sources
Sources Page

by activity

Most Active
Biggest Pipelines
Recently Active

hiring

Companies Hiring Now
Big Pharma Roles
All Companies →

Drugs & Pipeline

intelligence

Drugs
Patent Cliff

research

Publications
Topics

window

Next 90 Days
All (incl. Past)

by type

PDUFAs
Approvals
Earnings
Readouts

Sign In Subscribe

pharmadog

fetch the data · sniff the signal

Discover

Calendar
Drugs
Companies
News

Hubs

Topics
Jobs
Patent cliff
Publications

Tools

Compare
Search
Bookmarks

Trust

About
Sources
Contact

Legal

Privacy
Terms
Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

home
jobs
news
cal
search

Epivir · pharmadog

pharmadog
drugs
Epivir

drug

patient view →

lamivudine

Marketedupdated 2mo ago

by ViiV Healthcare Company

Approved

community read0 votes

all catalysts(0)

nothing on the calendar yet

News(0)

no news has mentioned this drug yet

brand

Epivir

generic

lamivudine

indication

Human Immunodeficiency Virus (HIV) Infections (AIDS)

phase

marketed

Data sources

ClinicalTrials.gov

last refreshed 53m ago

Found something off?

🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

Patent cliff

source: FDA Orange Book

first barrier falls

Mar 11, 2029

~2.7 years out

Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.

patents (2)

Sep 11, 2029patentUS 7754731*PED3.2y
Mar 11, 2029compositionUS 77547312.7y

comments(0)

5-min edit window · permanent after that

sign in to leave a comment · permanent archive after 5 minutes

no comments yet — first sniff?

🐶 often sniffed alongside

top 8

tagInfectious Disease2 co-mentions · 2 sources
drugEpivir-HBV2 co-mentions · 2 sources
drug(abacavir sulfate + dolutegravir sodium+ lamivudine) ODT1 co-mentions · 1 sources
drugabacavir sulfate1 co-mentions · 1 sources
drugTENOFOVIR DISOPROXIL FUMARATE1 co-mentions · 1 sources
drug(lamivudine + tenofovir disoproxil fumarate)1 co-mentions · 1 sources
drugAbacavir Sulfate Aurobindo1 co-mentions · 1 sources
drug(dolutegravir + lamivudine + tenofovir disoproxil fumarate)1 co-mentions · 1 sources

Trials studying lamivudine

phase3A Study to Evaluate the Efficacy, Safety, and Tolerability of Using an Oral Once-daily 2 Drug Regimen Compared to an Oral Once-daily 3 Drug Regimen for the Treatment of Human Immunodeficiency Virus (HIV)-1 in Adults Who Have Not Previously Taken Antiretroviral Therapyactive not recruitingn=307
phase3Prevention of HIV1 Mother to Child Transmission Without Nucleoside Analogue Reverse Transcriptase Inhibitors in the Pre-partum Phase. ANRS 135 Primevacompletedn=105
phase2A Phase 2b Study Evaluating Oral VH4524184 Regimens in Treatment Naïve Persons With HIV-1 (INNOVATE Study)recruitingn=150
phase3A Continued Access Study for Participants Transitioning From ViiV Healthcare-sponsored or ViiV Healthcare-collaborative Parent Studies for HIV Treatmentnot yet recruitingn=183
phase4Efficacy and Safety of Doravirine in the Rapid Initiationnot yet recruitingn=100
phase3DORAvirine Versus DOlutegravir Based Antiretroviral Regimens in Treatment-naïve People Living With HIV-1 Infectionrecruitingn=610
phase3Dolutegravir/Lamivudine Dual Therapy for ART-naïve People With HIV and TB Receiving Rifampin-based TB Treatmentrecruitingn=150
phase4Switch to Dolutegravir Plus Lamivudine Dual-Therapy in Transgender Women Living With HIV on Virologically Suppressive Antiretroviral Therapy (TRANS-SWITCH)recruitingn=50

more trials →